

HEPATOBIILIARY DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON

ROOM: ROSSETTI ROOM

SATURDAY MAY 4TH, 2024 10:30 AM – 11:30 AM

CO-CHAIRS : DR PAUL KARNICOLAS & DR VINCENT TAM

SENIOR INVESTIGATOR: DR CHRIS O'CALLAGHAN

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.

Learning Objectives:

- To identify and address, through clinical and translational research, the disease burden associated with malignancies of the colon in Canada.
- To identify clinical trial research opportunities in malignancies of the colon within the Canadian Cancer Trials Group.
- To integrate current knowledge regarding therapeutics and tumour biology in trial concept development and conduct as these relate to malignancies of the colon.
- To integrate and apply new clinical trial methodologies in malignancies of the colon in the Canadian Cancer Trials Group research agenda.
- To identify mentoring opportunities for new investigators.

10:30 am	Welcome	
10:35 am	HE.2 (SLIDE-HCC): Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable Hepatocellular Carcinoma	Dr V Tam
10:50 am	A Randomized phase III study of SBRT versus SBRT/STRIDE in patients with Child-Pugh B7 and B8 HCC	Dr M Yan & Dr L Dawson
11:05 am	Son of HE.1: Single fraction risk adapted radiotherapy for treatment refractory or end stage liver cancer: A Phase III Randomized Control Trial	Dr M Yan & Dr L Dawson
11:15 am	NCTN Hepatobiliary Taskforce Update	Dr V Tam & Dr P Karanicolas
11:30 am	Meeting Adjourned	

